Martin Willheim
Overview
Explore the profile of Martin Willheim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Balcar L, Schwarz M, Dorn L, Jachs M, Hartl L, Weseslindtner L, et al.
Liver Int
. 2024 Oct;
44(12):3151-3163.
PMID: 39351692
Background And Aims: Identification of people living with hepatitis C virus (HCV) via readily available laboratory records could be a key strategy for macro-elimination, aligning with the WHO elimination goal....
2.
Schwarz C, Bauer D, Dorn L, Jachs M, Hartl L, Chromy D, et al.
Wien Klin Wochenschr
. 2023 Sep;
136(9-10):278-288.
PMID: 37773541
Background And Aims: Micro-elimination projects targeted to specific hepatitis C virus (HCV) risk populations have been successful. Systematic identification of persons with HCV viremia, regardless of risk group, based on...
3.
Pilecky M, Harm S, Bauer C, Zottl J, Emprechtinger R, Eichhorn T, et al.
J Infect
. 2022 Jan;
84(4):579-613.
PMID: 35033581
No abstract available.
4.
Hackner K, Errhalt P, Willheim M, Schragel F, Grasl M, Lagumdzija J, et al.
GMS Hyg Infect Control
. 2020 Nov;
15:Doc28.
PMID: 33214993
New commercially available point-of-care (POC) immunodiagnostic tests are appearing, which may yield rapid results for anti-SARS-CoV-2 antibodies. The aim of this study was to evaluate the diagnostic accuracy of rapid...
5.
Bolomsky A, Muller J, Stangelberger K, Lejeune M, Duray E, Breid H, et al.
Br J Haematol
. 2020 Apr;
190(6):877-890.
PMID: 32232850
Future progress in the treatment of multiple myeloma (MM) requires both the characterisation of key drivers of the disease and novel, innovative approaches to tackle these vulnerabilities. The present study...
6.
Draxler D, Wutzlhofer L, Slavka G, Hubl W, Ludwig H, Schreder M, et al.
Indian J Hematol Blood Transfus
. 2019 Nov;
35(4):673-682.
PMID: 31741619
Increasing interest has been expressed for flow cytometric immunophenotyping for diagnosis and monitoring in plasma cell dyscrasias over the last decades. The aim of this investigation was to compare the...
7.
Tscharre M, Farhan S, Bruno V, Rohla M, Egger F, Weiss T, et al.
Eur J Clin Invest
. 2019 Jul;
49(9):e13157.
PMID: 31318979
Background: Increased platelet turnover and high platelet reactivity are associated with short-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) or stable coronary...
8.
Gruber S, Freynhofer M, Willheim M, Weiss T, Egger F, Hubl W, et al.
Platelets
. 2018 Jun;
30(4):506-512.
PMID: 29869937
Long-term evidence shows an increased risk of cardiovascular events in the morning hours and recent studies in aspirin-treated patients have shown increased platelet reactivity at the end of the dosing...
9.
Freynhofer M, Iliev L, Bruno V, Rohla M, Egger F, Weiss T, et al.
Thromb Haemost
. 2017 Feb;
117(5):923-933.
PMID: 28229159
Elevated platelet turnover contributes to high platelet reactivity. High platelet reactivity after percutaneous coronary intervention (PCI) is associated with major adverse cardiovascular events (MACE). The purpose of this study was...
10.
Bolomsky A, Hubl W, Spada S, Muldur E, Schlangen K, Heintel D, et al.
Am J Hematol
. 2017 Jan;
92(3):269-278.
PMID: 28052520
Immunomodulatory drugs (IMiDs) are a cornerstone in the treatment of multiple myeloma (MM), but specific markers to predict outcome are still missing. Recent work pointed to a prognostic role for...